Literature DB >> 21271234

[Epidermolysis bullosa : Diagnosis and therapy].

C Has1, L Bruckner-Tuderman.   

Abstract

Hereditary epidermolysis bullosa is characterized by mechanically induced blistering of the skin and mucous membranes. The causative mechanisms are based on mutations in genes for structural proteins of the epidermis and the dermal-epidermal junction zone. EB is genetically and clinically heterogeneous. Based on the clinical phenotype alone, the diagnosis is difficult in newborns and toddlers, and sometimes even in adults. A precise diagnosis is only possible with laboratory tests like immunofluorescence mapping, electron microscopy and mutation analysis in specialized centers. The treatment is symptomatic and based on the principles of good wound management and - for severe cases - on multidisciplinary care. New data on the pathogenetic mechanisms of epidermolysis bullosa deliver perspectives for development of novel molecular therapies.

Mesh:

Substances:

Year:  2011        PMID: 21271234     DOI: 10.1007/s00105-010-2049-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

Review 1.  Progress in epidermolysis bullosa research: toward treatment and cure.

Authors:  Jouni Uitto; John A McGrath; Ulrich Rodeck; Leena Bruckner-Tuderman; E Clare Robinson
Journal:  J Invest Dermatol       Date:  2010-04-15       Impact factor: 8.551

2.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

Review 3.  Network epidermolysis bullosa: molecular pathomechanisms and novel therapeutic approaches.

Authors:  Andreas Volz; Cristina Has; Hauke Schumann; Leena Bruckner-Tuderman
Journal:  J Dtsch Dermatol Ges       Date:  2007-04       Impact factor: 5.584

4.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

5.  Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.

Authors:  Mei Chen; Noriyuki Kasahara; Douglas R Keene; Lawrence Chan; Warren K Hoeffler; Deborah Finlay; Maria Barcova; Paula M Cannon; Constance Mazurek; David T Woodley
Journal:  Nat Genet       Date:  2002-11-11       Impact factor: 38.330

6.  A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex.

Authors:  Richard W Groves; Lu Liu; Patricia J Dopping-Hepenstal; Hugh S Markus; Patricia A Lovell; Linda Ozoemena; Joey E Lai-Cheong; Jeffrey Gawler; Katsushi Owaribe; Takashi Hashimoto; Jemima E Mellerio; John B Mee; John A McGrath
Journal:  J Invest Dermatol       Date:  2010-02-18       Impact factor: 8.551

7.  Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

8.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 9.  Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literature.

Authors:  Ningning Dang; Sandra Klingberg; Adam I Rubin; Matthew Edwards; Siegfried Borelli; John Relic; Penelope Marr; Kim Tran; Anne Turner; Nicholas Smith; Dedee F Murrell
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

10.  Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.

Authors:  Fulvio Mavilio; Graziella Pellegrini; Stefano Ferrari; Francesca Di Nunzio; Enzo Di Iorio; Alessandra Recchia; Giulietta Maruggi; Giuliana Ferrari; Elena Provasi; Chiara Bonini; Sergio Capurro; Andrea Conti; Cristina Magnoni; Alberto Giannetti; Michele De Luca
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  5 in total

Review 1.  [Interdisciplinary care of newborns with epidermolysis bullosa and severe congenital ichthyoses].

Authors:  H Ott; F Guthmann; B Ludwikowski
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

Review 2.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

3.  [Parallels between wound healing, chronic inflammatory skin diseases and neoplasia: clinical aspects].

Authors:  A Brown; I Tantcheva-Poor; S A Eming
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

Review 4.  [Hereditary epidermolysis bullosa in school children and adolescents. Clinical picture and interdisciplinary management].

Authors:  H Ott; C Eich; K Schriek; B Ludwikowski
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

5.  [The many facets of inherited skin fragility].

Authors:  C Has; D Kiritsi
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.